LncRNA HCP5 is Highly Expressed in Gestational Diabetes Mellitus to Suppress Insulin Secretion
Hu Zhao,Jun Zhan,Qiong Wang,Shuqi Yang,Xue Xiao
DOI: https://doi.org/10.2147/dmso.s409365
2024-01-10
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Hu Zhao, 1, &ast Jun Zhan, 1, &ast Qiong Wang, 2 Shuqi Yang, 1 Xue Xiao 1 1 Department of Gynecology and Obstetrics, Sichuan University West China Second University Hospital, Chengdu, Sichuan, People's Republic of China; 2 Department of Gynecology and Obstetrics, Chengdu Women and Children's Central Hospital, Chengdu, Sichuan, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xue Xiao, Department of Gynecology and Obstetrics, Sichuan University West China Second University Hospital, No. 20, Section 3, Renmin Road South, Chengdu, Sichuan, 610041, People's Republic of China, Email Purpose: LncRNA HCP5 has been reported to participate in high glucose-induced pathological processes, whereas its role in gestational diabetes mellitus (GDM) is unclear. This study aimed to explore the role of HCP5 in GDM. Methods: This study enrolled a total of 220 pregnant women (gestational age = 1 month). A follow-up study was performed until delivery. The occurrence of GDM was checked every month during follow-up. Plasma samples were collected from all participants and expression of HCP5 was determined with RT-qPCR. The 220 patients were divided into high and low GDM groups, and GDM-free curves were plotted for both groups and compared. The ROC curve was plotted to explore the predictive value of plasma HCP5 on the day of admission for GDM. INS-1 cells were transfected with HCP5 expression vector or siRNA, and cell viability under high glucose was determined by the MTT assay. An ELISA was applied to determine insulin levels in the cell culture medium. Results: During follow-up, the level of HCP5 was increased during pregnancy and the high HCP5 level group showed a significantly higher incidence of GDM. Plasma levels of HCP5 on the day of admission effectively separated GDM patients from healthy controls. HCP5 negatively regulated cell viability and insulin secretion under high glucose treatment. Conclusion: HCP5 may act as a predictor for GDM, and it negatively regulated INS-1 cell viability and insulin secretion under high glucose conditions. Keywords: HCP5, gestational diabetes mellitus, INS-1 cells, insulin Gestational diabetes mellitus (GDM) is a type of diabetes caused by glucose intolerance in pregnant women with no previous history of diabetes. 1,2 Differently from type 1 diabetes, which is caused by the insufficient production of insulin, the mechanism of GDM is unclear. Without proper treatment, GDM may cause a series of adverse events, such as early birth, stillbirth, and breathing difficulties. 3,4 GDM can also increase the long-term risk of cardiovascular diseases in mothers. 5 GDM can be treated with insulin injection or by maintaining a healthy diet. 6 However, insulin therapy or a healthy diet cannot fully prevent the offspring from developing metabolic disorders. 6 At present, early prediction and intervention are still important. Previous studies have made numerous efforts to develop biomarkers for the early detection of GDM. 7–9 These biomarkers may include total cholesterol, triglycerides, low-density lipids, and serum uric acid. 7–9 Neural networks have also shown potential in the early detection of GDM. 8 However, these markers and methods are limited by unsatisfactory sensitivity and specificity. 7–9 The participation of molecular factors is a requirement for the development of GDM. 10 Some factors with important roles in GDM are likely biomarkers for this disease and its complications. 11 In many human clinical disorders, including GDM, lncRNAs indirectly affect protein synthesis, rather than directly coding proteins, to regulate disease development. 12 Therefore, lncRNAs are a goldmine for the development of biomarkers to detect GDM. However, the expression and function of most lncRNAs in GDM are unclear. LncRNA HCP5 has been reported to participate in high glucose-induced pathological processes, 13 suggesting its potential participation in GDM, but the role of LncRNA HCP5 is unclear. This study aimed to explore the role of HCP5 in GDM, with a focus on its clinical values. This study enrolled a total of 220 pregnant women (age = 26.7±3.1 years; gestational age = 1 month). All participants were enrolled at West China Second University Hospital between May 2019 and April 2020 after the Ethics Committee of this hospital had approved this study. The inclusion criteria were ≥18 years old, time from last menstrual period ≥1 month, and a pregnancy confirmed by β-hCG testing. Women who had diabetes before pregnancy were excluded. A follow-up stud -Abstract Truncated-
endocrinology & metabolism